The chief executive of AIM-listed medical tech group Tissue Regenix has stepped down with immediate effect.
The Leeds-based company did not reveal the reasons behind Antony Odell’s departure but said that its board will commence a process for appointment of a new CEO.
In the interim, non-executive chairman John Samuel has assumed the role of executive chairman.
He said: “The board of directors and I would like to thank Antony for his dedication and commitment to Tissue Regenix since he was appointed CEO in 2008. He has been a key member of the executive team.
“During his tenure the company has listed on the AIM market, successfully commercialised products in the US and earlier this year completed the transformational acquisition of CellRight, while continuing to pursue additional commercial opportunities.
“We wish him every success in his future career.”
Tissue Regenix is an international medical technology company specialising in the field of regenerative medicine, making replacement body parts using biological tissues.
The business was spun out of the University of Leeds in 2006 and listed on the AIM market of the London Stock Exchange in 2010.
It operates from a UK office in Leeds and a US base in Texas.